PDCD1 and neoplasm: The latest research findings indicate that administering the Janus kinase 1 (JAK1) inhibitor itacitinib following anti-PD-1 (programmed cell death protein 1) immunotherapy enhances immune function and the anti-tumor response in mice (Mathew et al., 2024).